LRRK2 and Parkinson disease: We found that increased mtDNA damage in PD patient-derived immune cells heterozygous for the G2019S LRRK2 mutation was abrogated following treatment with multiple classes of LRRK2 kinase inhibitors and correlated with measures of pSer935 LRRK2 dephosphorylation44,49.